IV Saline Recalled Nationwide After Potential Fibreglass Contamination Raises Risk of Blood Clots and Death

Hospitals across fourteen US states have been ordered to immediately stop using two specific lots of intravenous saline after manufacturer Baxter International discovered fibreglass particles inside the sealed bags.

The voluntary nationwide recall, announced on 25 August 2026, covers 0.9% Sodium Chloride Injection distributed in 500 mL VIAFLEX plastic containers. The product is a staple fluid used in emergency rooms, operating theatres and dialysis units nationwide.

Baxter confirmed the fibreglass was identified as particulate matter within the solution itself, not the packaging. The U.S. Food and Drug Administration (FDA) published the company's recall notice the following day, warning that the contamination carries the potential for blood clots, organ damage and death.

What Baxter Found and Which States Are Affected

The recall affects a single product code, 2B1323Q, tied to two lot numbers: Y495523 and Y495523A, both carrying an expiration date of 31 October 2027. The National Drug Code identifying the affected product is 0338-0049-03.

According to Baxter's company announcement, published via the FDA's recall portal, the contaminated saline was shipped between 31 July 2026 and 3 August 2026 to healthcare providers and distributors across Florida, Illinois, Indiana, Louisiana, Maryland, Missouri, North Carolina, New Jersey, Nevada, New York, Ohio, South Carolina, Texas and Virginia.

Each case contained 24 units of the product, meaning the contaminated fluid could have reached a substantial number of hospital wards, surgical suites and dialysis clinics before detection.

The product is used both as a general source of water and electrolytes for patients and as a priming solution in haemodialysis procedures, placing dialysis patients, who are frequently among the most medically vulnerable, directly in the path of the recall.

How Fibreglass in an IV Line Can Kill

Baxter's own risk statement, filed with the FDA, does not mince words about the danger. 'Intravenous administration of 0.9% Sodium Chloride Injection containing fibre glass particulate matter may lead to serious adverse health consequences,' the company said in its announcement.

It went on to warn that the particles 'can cause blockage and clotting in blood vessels, which can cut off blood flow to vital organs, lead to a life-threatening blood clot in the lungs (pulmonary embolism) and cause permanent organ damage or death.'

Baxter further noted that the fibreglass fragments could trigger local vein irritation, inflammatory reactions, aggravation of pre-existing infections and allergic reactions in patients receiving the fluid intravenously.

As of 25 August 2026, the date of the company's announcement, Baxter said it had not received any reports of adverse events connected to the affected lots. The mechanism of harm is straightforward but severe.

When rigid particulate matter such as fibreglass enters the bloodstream through an IV line, it can lodge in narrow blood vessels, restricting circulation to organs including the lungs, kidneys and brain. In the most serious cases, this blockage can starve tissue of oxygen entirely, a complication that can prove fatal within hours if untreated.

Baxter's Recall Instructions and What Patients Should Do

Baxter said it is directly contacting affected customers by email with instructions on how to identify and return the impacted product. It has instructed healthcare facilities to 'immediately discontinue use of and return all affected units in accordance with their facility's process.'

The company has set up a dedicated consumer line, 888-229-0001, staffed from 7:00 am to 6:00 pm Central Time, Monday through Friday, for providers and patients with questions.

Patients or clinicians who believe they have experienced a problem connected to the recalled saline are being directed to two channels.

The first is their own physician or healthcare provider, for immediate clinical concerns. The second is the FDA's MedWatch Adverse Event Reporting programme, which can be accessed online, by fax, or by mailing a completed reporting form to the agency.

This is not the first time Baxter, one of the largest suppliers of IV fluids to American hospitals, has faced a saline-related recall.

The company pulled a lot of Heparin Sodium in 0.9% Sodium Chloride Injection in August 2024 over elevated endotoxin levels, and has previously recalled IV solutions after particulate matter, in that case insect fragments, was discovered in sealed containers.

The FDA has classified the current action as a company-initiated voluntary recall, and the agency confirmed it has been formally notified of Baxter's decision.

For now, hospitals in the fourteen affected states are working through inventories to isolate and return the two contaminated lots, while the FDA continues to monitor for any adverse event reports tied to the fibreglass contamination.